Table 1.

Characteristics of patients on SABA over-use, on PRT with high OCS exposure, and on PRT

	SABA over-use (23.9 per 100,000)		PRT with high OCS exposure (101.2 per 100,000)		PRT (4786.5 per 100,000)
Sex (%) 95% CI
Female	29.5	18.2–44.2	50.0	42.9–57.1	55.9	54.9–56.9
Male	70.5	55.8–81.8	50.0	42.9–57.1	44.1	43.1–45.1
Age, med P25–P75	61.0	50.8–73.5	69.0	57.3–78.8	64.0	47.0–76.0
Age (%) 95% CI
15:44	11.4	5.0–24.0	8.1	4.9–12.9	28.8	27.9–29.8
45:64	45.5	31.7–59.9	30.1	24.0–37.0	21.8	20.9–22.6
> 64	43.2	29.7–57.8	61.8	54.7–68.5	49.4	48.3–50.4
Maintenance-to-total prescribed (%) 95% CI
No controller prescribed	15.9	7.9–29.4	–		–
> 0 to 20%	25.0	14.6–39.4	2.7	1.2–6.1	0.3	0.2–0.4
≥ 20 to < 50%	31.8	20.0–46.6	35.5	29.0–42.6	3.3	2.9–3.7
≥ 50 to < 70%	20.5	11.1–34.5	28.5	22.5–35.4	8.2	7.6–8.8
≥ 70 to < 90%	6.8	2.3–18.2	28.0	22.0–34.8	16.3	15.5–17.1
≥ 90 to 100%	0.0	0.0–8.0	5.4	2.9–9.6	72.0	71.0–72.9
Primary adherence to controller medication (%) 95% CI
0%	10.8	4.3–24.7	3.8	1.8–7.6	6.9	6.4–7.4
> 0 to 20%	5.4	1.5–1.8	5.4	2.9–9.6	5.2	4.8–5.7
> 20 to 50%	13.5	5.9–27.9	31.7	25.4–38.7	28.2	27.3–29.1
> 50 to 70%	13.5	5.9–27.9	23.1	17.6–29.7	18.1	17.2–18.9
> 70 to 90%	35.1	21.8–51.2	21.0	15.7–27.4	19.4	18.6–20.2
> 90 to 100%	21.6	11.4–37.2	15.1	10.6–20.9	22.3	21.4–23.1

PRT persistent respiratory treatment, SABA short-acting beta2 agonist, OCS oral corticosteroids